Akcay et al. revealed that treatment with high-dose exogenous IL-33 (1 μg, twice a day on days 1, 2, and 3 after cisplatin administration, i.p. injection) exacerbates cisplatin-induced AKI via CD4 T-cells/CXCL1 axis in the mouse model [20]. This evidence concerns the gene IL33 and acute kidney injury.